ADAPTIMMUNE THERAPEUTICS-ADR (ADAP)

US00653A1079 - ADR

0.6049  +0 (+0.82%)

Premarket: 0.6034 0 (-0.25%)

ADAPTIMMUNE THERAPEUTICS-ADR

NASDAQ:ADAP (12/20/2024, 8:00:00 PM)

Premarket: 0.6034 0 (-0.25%)

0.6049

+0 (+0.82%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%95%
Sales Q2Q%458.83%
CRS25.55
6 Month-32.03%
Overview
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Ins Owners0.28%
Inst Owners61.77%
Market Cap154.78M
Shares255.88M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts77.33
Short Float %2.64%
Short Ratio3.46
IPO05-06 2015-05-06
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ADAP Daily chart

Company Profile

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. The company is headquartered in Abingdon, Oxfordshire and currently employs 449 full-time employees. The company went IPO on 2015-05-06. The firm is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The firm is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.

Company Info

ADAPTIMMUNE THERAPEUTICS-ADR

60 Jubilee Avenue, Milton Park

Abingdon OXFORDSHIRE OX14 4RX

P: 441235430000

CEO: Adrian Rawcliffe

Employees: 449

Website: https://www.adaptimmune.com/

ADAP News

News Image4 days ago - NewsfileAdaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31,...

News Image21 days ago - NewsfileFirst Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company...

News Imagea month ago - NewsfileAdaptimmune Reports Q3 2024 Financial and Business Updates

Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed...

News Imagea month ago - NewsfileAdaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-celResults include six complete responses...

News Image2 months ago - NewsfileAdaptimmune to Participate in Scientific and Medical Conferences this November and December

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working...

News Image2 months ago - NewsfileAdaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...

ADAP Twits

Here you can normally see the latest stock twits on ADAP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example